Paul Jeng
Stock Analyst at Guggenheim
(2.85)
# 1,867
Out of 5,111 analysts
6
Total ratings
80%
Success rate
20.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Initiates: Buy | $9 | $1.75 | +414.29% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.04 | +89.24% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $36.80 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $1.04 | +380.77% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $34.03 | +46.93% | 1 | Sep 18, 2025 |
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $1.75
Upside: +414.29%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.04
Upside: +89.24%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $36.80
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $1.04
Upside: +380.77%
IDEAYA Biosciences
Sep 18, 2025
Initiates: Buy
Price Target: $50
Current: $34.03
Upside: +46.93%